pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Apixaban
drug · small molecule
save

apixaban

pre_registrationupdated 6mo ago
by Taho Pharmaceuticals Ltd🔗 ChEMBL
community read0 votes

🐶 often sniffed alongside

top 8
  • drugapixaban ER5 co-mentions · 2 sources
  • drugapixaban ODT5 co-mentions · 2 sources
  • tagOncology2 co-mentions · 1 sources
  • tagHematology2 co-mentions · 1 sources
  • tagAdCom2 co-mentions · 1 sources
  • tag510(k) Clearance2 co-mentions · 1 sources
  • tagDiagnostics Company2 co-mentions · 1 sources
  • companyMedical University of Gdansk1 co-mentions · 1 sources

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 8 approved and 14 investigational indications.

targets

Coagulation factor X

all catalysts(0)

nothing on the calendar yet

Trials studying apixaban

  • phase3Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillationrecruitingn=15,364
  • phase3Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancersrecruitingn=1,600
  • phase2Vortosiran in Atrial Fibrillationnot yet recruitingn=150
  • phase3REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adultsrecruitingn=2,000
  • phase1Single Dose Trial of VMX-C001 in Healthy Subjects With and Without FXa Direct Oral Anticoagulantcompletedn=40
  • N/ADEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosisrecruitingn=300
  • phase2Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulationrecruitingn=1,200
  • phase3A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillationactive not recruitingn=20,284

News(10)

  • Merck scraps centerpiece of $2.7B ArQule buy after late-stage safety concerns
    Merck is canning multiple Phase 3 studies of nemtabrutinib after a benefit-risk review derailed hopes of the asset entering the non-covalent BTK inhibitor race.
    biospace · 21h ago
  • Blackstone bets $1.5B on Pfizer’s obesity drug
    The deal will support a sprawling Phase 3 program for a monthly GLP-1 shot Pfizer acquired by winning a bidding war for the drug’s previous owner, Metsera.
    biopharma_dive · 6d ago
  • Bristol Myers research chief to depart in ‘evolution’ of company’s structure
    Robert Plenge is leaving as part of a shift that will see the company merge together its R&D department in a bid to speed development and capitalize on new technologies.
    biopharma_dive · 6d ago
  • Pfizer snags $1.5B financing from PE firm Blackstone to support Metsera asset
    With 10 active or planned Phase 3 trials underway for Metsera’s berobenatide, Pfizer has signed a deal with Blackstone Life Sciences to finance the program to approval.
    biospace · 6d ago
  • BMS R&D head to depart amid restructure
    Bristol Myers Squibb is combining all research and development efforts under one leader as pressure rises to replenish its pipeline.
    biospace · 6d ago
  • Bayer wins first-in-class FDA nod for blood thinner, setting stage for BMS-J&J rival
    Bayer’s Sunharbo has secured the first FDA approval of its class, establishing a regulatory pathway for other factor XIa inhibitors, such as Bristol Myers Squibb and Johnson and Johnson’s milvexian.
    biospace · 8d ago
  • Pfizer flat in Q3 despite 32% growth for new and acquired products
    Sales of assets from Seagen and Biohaven grew in the third quarter, but it wasn’t enough for Pfizer to overcome declines across the Prevnar and COVID franchises.
    biospace · 15d ago
  • BMS drops Prothena-partnered neuro drug, sales outlook improves on a Q3 beat
    In addition to canning an Orum-acquired blood cancer candidate last month, Bristol Myers Squibb cut a Prothena-partnered neuro asset in the third quarter. But with sales climbing 7%, the Big Pharma…
    biospace · 20d ago
  • J&J’s disappointing Q3, RevMed’s subgroup data, BMS’ ‘mixed’ results, Caribou’s cutback
    Johnson & Johnson beat analyst expectations in the third quarter but left Wall Street wanting more; BMS dominated the news cycle on Monday with a Phase 3 win validating its $4.1 billion RayzeBio bu…
    biospace · 1mo ago
  • BMS’ Phase 3 win for lung drug clouded by high-dose miss
    A low-dose win could derisk a regulatory pathway for BMS’ LPA1 antagonist in idiopathic pulmonary fibrosis after a recently reported patient death, but a miss at the higher dose leaves analysts awa…
    biospace · 1mo ago
view all news mentions →
brand
Apixaban
trade names
Apixaban accord, Eliquis
generic
apixaban
MOA
Coagulation factor X inhibitor
indication
Atrial Fibrillation
phase
pre_registration
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 2h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?